BRPI0914223A2 - derivados de tiofeno ou tiazol e seus usos como inibidores de p13k - Google Patents

derivados de tiofeno ou tiazol e seus usos como inibidores de p13k

Info

Publication number
BRPI0914223A2
BRPI0914223A2 BRPI0914223A BRPI0914223A BRPI0914223A2 BR PI0914223 A2 BRPI0914223 A2 BR PI0914223A2 BR PI0914223 A BRPI0914223 A BR PI0914223A BR PI0914223 A BRPI0914223 A BR PI0914223A BR PI0914223 A2 BRPI0914223 A2 BR PI0914223A2
Authority
BR
Brazil
Prior art keywords
thiophene
inhibitors
thiazole derivatives
thiazole
derivatives
Prior art date
Application number
BRPI0914223A
Other languages
English (en)
Portuguese (pt)
Inventor
C Renou Christelle
P Cardin David
L Gaulin Jeffrey
D Greenspan Paul
Vyskocil Stepan
Xu Tianlin
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41010579&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0914223(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of BRPI0914223A2 publication Critical patent/BRPI0914223A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0914223A 2008-06-19 2009-06-17 derivados de tiofeno ou tiazol e seus usos como inibidores de p13k BRPI0914223A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13248408P 2008-06-19 2008-06-19
PCT/US2009/003607 WO2009154741A1 (en) 2008-06-19 2009-06-17 Thiophene or thiazole derivatives and their use as pi3k inhibitors

Publications (1)

Publication Number Publication Date
BRPI0914223A2 true BRPI0914223A2 (pt) 2019-09-24

Family

ID=41010579

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0914223A BRPI0914223A2 (pt) 2008-06-19 2009-06-17 derivados de tiofeno ou tiazol e seus usos como inibidores de p13k

Country Status (21)

Country Link
US (3) US8183240B2 (https=)
EP (1) EP2313399B1 (https=)
JP (1) JP5596026B2 (https=)
KR (1) KR20110018451A (https=)
CN (1) CN102066365A (https=)
AU (1) AU2009260782B2 (https=)
BR (1) BRPI0914223A2 (https=)
CA (1) CA2727069A1 (https=)
CL (1) CL2010001474A1 (https=)
CO (1) CO6331431A2 (https=)
CR (1) CR20110032A (https=)
EA (1) EA201170052A1 (https=)
ES (1) ES2491522T3 (https=)
GE (1) GEP20125650B (https=)
IL (1) IL210055A0 (https=)
MA (1) MA32468B1 (https=)
MX (1) MX2010014125A (https=)
NZ (1) NZ589844A (https=)
UA (1) UA106206C2 (https=)
WO (1) WO2009154741A1 (https=)
ZA (1) ZA201008875B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5581219B2 (ja) 2008-01-25 2014-08-27 ミレニアム ファーマシューティカルズ， インコーポレイテッド チオフェンおよびホスファチジルイノシトール３−キナーゼ（ｐｉ３ｋ）阻害薬としてのその使用
JP5596026B2 (ja) * 2008-06-19 2014-09-24 ミレニアム ファーマシューティカルズ， インコーポレイテッド チオフェン又はチアゾール誘導体及びｐｉ３ｋ阻害剤としてのそれらの使用
WO2010090716A1 (en) * 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
US9090601B2 (en) * 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
MX2013001660A (es) * 2010-08-11 2013-06-03 Millenium Pharmaceuticals Inc Heteroarilos y usos de los mismos.
WO2012021611A1 (en) * 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US8859768B2 (en) 2010-08-11 2014-10-14 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
JP5726635B2 (ja) 2010-08-25 2015-06-03 株式会社Ｎｔｔドコモ マルチモードフロントエンド回路
TW201307309A (zh) 2010-10-13 2013-02-16 Millennium Pharm Inc 雜芳基化合物及其用途
CN102503930B (zh) * 2011-10-28 2014-07-02 浙江大学 3,4,5,-三取代氨基噻吩类化合物及其制备和用途
DK2790705T3 (en) 2011-12-15 2018-03-12 Novartis Ag Use of inhibitors of the activity or function of PI3K
WO2013096630A1 (en) * 2011-12-23 2013-06-27 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
EP2825889A4 (en) * 2012-03-14 2015-10-28 Salk Inst For Biological Studi ADENOVIRAL TUMOR DIAGNOSIS
AU2014236207B2 (en) 2013-03-14 2019-05-23 Salk Institute For Biological Studies Oncolytic adenovirus compositions
WO2014144850A1 (en) 2013-03-15 2014-09-18 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
BR112016018691A2 (pt) * 2014-02-14 2017-08-08 Univ British Columbia Compostos do domínio de ligação ao dna (dbd) de receptor de andrógeno humano como terapêuticos e métodos para seu uso
KR20250081944A (ko) 2014-09-24 2025-06-05 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양 살상 바이러스 및 이의 사용방법
EP4155411A1 (en) 2016-02-23 2023-03-29 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
EP3532082A4 (en) 2016-12-12 2020-08-26 Salk Institute for Biological Studies SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES
MX2020010499A (es) 2018-04-09 2020-10-28 Salk Inst For Biological Studi Composiciones de adenovirus oncoliticas con propiedades aumentadas de replicacion.
WO2020261144A1 (en) * 2019-06-28 2020-12-30 Pfizer Inc. 5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases
CN110759900B (zh) * 2019-10-25 2021-07-30 沈阳药科大学 噻吩类化合物的制备方法和用途
US20230046892A1 (en) 2019-12-20 2023-02-16 Bayer Aktiengesellschaft Substituted thiophene carboxamides, thiophene carboxylic acids and derivatives thereof
CN113527281B (zh) * 2020-04-20 2023-12-22 昆山彭济凯丰生物科技有限公司 杂环化合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD275870A1 (de) 1988-09-27 1990-02-07 Univ Leipzig Verfahren zur herstellung von in 5-position verschiedenartig substituierten 3-aminothiophen-4-carbonitrilen
WO2006078287A2 (en) 2004-05-06 2006-07-27 Plexxikon, Inc. Pde4b inhibitors and uses therefor
GB0508472D0 (en) * 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
MX2008013578A (es) 2006-04-26 2009-03-23 Hoffmann La Roche Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k).
EP2016075A1 (en) * 2006-05-03 2009-01-21 AstraZeneca AB Thiazole derivatives and their use as anti-tumour agents
MX2009002046A (es) 2006-08-24 2009-03-06 Astrazeneca Ab Derivados de morfolino pirimidina utiles en el tratamiento de trastornos proliferativos.
WO2009042607A1 (en) * 2007-09-24 2009-04-02 Genentech, Inc. Thiazolopyrimidine p13k inhibitor compounds and methods of use
JP5581219B2 (ja) * 2008-01-25 2014-08-27 ミレニアム ファーマシューティカルズ， インコーポレイテッド チオフェンおよびホスファチジルイノシトール３−キナーゼ（ｐｉ３ｋ）阻害薬としてのその使用
JP5596026B2 (ja) * 2008-06-19 2014-09-24 ミレニアム ファーマシューティカルズ， インコーポレイテッド チオフェン又はチアゾール誘導体及びｐｉ３ｋ阻害剤としてのそれらの使用

Also Published As

Publication number Publication date
US8183240B2 (en) 2012-05-22
CO6331431A2 (es) 2011-10-20
IL210055A0 (en) 2011-02-28
CR20110032A (es) 2011-03-14
CN102066365A (zh) 2011-05-18
WO2009154741A1 (en) 2009-12-23
US20100075951A1 (en) 2010-03-25
AU2009260782A1 (en) 2009-12-23
MA32468B1 (fr) 2011-07-03
US20130217689A1 (en) 2013-08-22
EP2313399A1 (en) 2011-04-27
WO2009154741A8 (en) 2010-03-25
ES2491522T3 (es) 2014-09-08
JP2011524904A (ja) 2011-09-08
CA2727069A1 (en) 2009-12-23
ZA201008875B (en) 2012-02-29
UA106206C2 (ru) 2014-08-11
CL2010001474A1 (es) 2011-04-29
JP5596026B2 (ja) 2014-09-24
MX2010014125A (es) 2011-02-24
US8440664B2 (en) 2013-05-14
AU2009260782B2 (en) 2014-12-11
KR20110018451A (ko) 2011-02-23
EA201170052A1 (ru) 2011-06-30
US20120202812A1 (en) 2012-08-09
NZ589844A (en) 2012-11-30
GEP20125650B (en) 2012-09-25
EP2313399B1 (en) 2014-05-28

Similar Documents

Publication Publication Date Title
BRPI0914223A2 (pt) derivados de tiofeno ou tiazol e seus usos como inibidores de p13k
BR112012000660A2 (pt) compostos heterociclos e seus usos
BR112012003709A2 (pt) compostos heterocíclicos e usos dos mesmos
BRPI1016150A2 (pt) compostos heterocíclicos e seus usos.
BRPI0921862A2 (pt) inibidores de raf e seus usos
BRPI0908906A2 (pt) compostos heterocíclicos e usos dos mesmos
BRPI0919322A2 (pt) derivados de glicosideo e usos dos mesmos como inibidores sglt
BR112012013175A2 (pt) 2-amino-5,5-diflúor-5,6-di-hidro-4h-oxazinas como inibidores de bace 1 e/ou bace 2
EP2505173A4 (en) VOIDABLE ARTICLE
EP2409673A4 (en) VOIDABLE ARTICLE
EP2500003A4 (en) VOIDABLE ARTICLE
BRPI0906625A2 (pt) Derivados de tio-2-amino-quinolina-6-substituída úteis como inibidores da beta-secretase (bace)
BRPI1011066A2 (pt) "pirazolopirimidinas e heterociclos relacionados como inibidores de quinase
BRPI0920767A2 (pt) Tiazóis substituídos por heterociclila como agentes protetores de cultura
BRPI0906980A2 (pt) Composição de derivados e maleatados
PT2513105E (pt) Derivados de 2-arilimidazole como inibidores da enzima pde10a
BRPI0909185A2 (pt) Derivado de vitamina e e seus usos
BRPI1012679A2 (pt) derivados de piperidina e piperazina como inibidores de autotaxina
BRPI0917557A2 (pt) artigo absorvente com componente de barreira
BRPI0820722A2 (pt) Derivados de tiazol usados como inibidores de pi 3 cinases
BRPI0812825A2 (pt) Derivados ftalazinona como inibidores de parp-1
BRPI1012770A2 (pt) derivados de tiofeno
BRPI0920927A2 (pt) derivados de azaquinolinona e usos dos mesmos
BRPI0920183A2 (pt) derivados de fenetilamida e seus analogos heterociclicos
EP2415437A4 (en) VOIDABLE ARTICLE

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.